Icaritin reduces oral squamous cell carcinoma progression via the inhibition of STAT3 signaling

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Yang, Jian Guang ^a   Lu, Rui ^a   Ye, Xiao Jing ^a   Zhang, Jing ^a   Tan, Ya Qin ^a   Zhou, Gang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Icaritin; Oral squamous cell carcinoma; Premalignant lesion; Signal transducer and activator of transcription 3

Indexed keywords

BECLIN 1; CASPASE 3; CHINESE DRUG; CYCLIN A2; CYCLIN D1; ICARITIN; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; CYCLINE; FLAVONOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GROWTH; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC50; INTRACELLULAR SIGNALING; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; METABOLISM; MOUTH NEOPLASMS; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLINS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLAVONOIDS; HUMANS; MICE, INBRED C57BL; MOUTH NEOPLASMS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS;

EID: 85009844383     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010132     Document Type: Article

References (44)

1. Adams, D. Oral cancer: Early diagnosis. Dent. Today 2014, 33, 8.
2. Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108.
3. Guneri, P.; Epstein, J.B. Late stage diagnosis of oral cancer: Components and possible solutions. Oral Oncol. 2014, 50, 1131–1136.
4. Kumar, M.; Nanavati, R.; Modi, T.G.; Dobariya, C. Oral cancer: Etiology and risk factors: A review. J. Cancer Res. Ther. 2016, 12, 458–463.
5. Boy, S.C. Leukoplakia and erythroplakia of the oral mucosa—A brief overview. SADJ J. S. Afr. Dent. Assoc. 2012, 67, 558–560.
6. Warnakulasuriya, S.; Reibel, J.; Bouquot, J.; Dabelsteen, E. Oral epithelial dysplasia classification systems: Predictive value, utility, weaknesses and scope for improvement. J. Oral Pathol. Med. 2008, 37, 127–133.
7. + -induced toxicity in MES23.5 cells. Eur. J. Pharmacol. 2016, 786, 53–59.
8. Wo, Y.B.; Zhu, D.Y.; Hu, Y.; Wang, Z.Q.; Liu, J.; Lou, Y.J. Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J. Cell. Biochem. 2008, 103, 1536–1550.
9. Huang, X.; Zhu, D.; Lou, Y. A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur. J. Pharmacol. 2007, 564, 26–36.
10. Tong, J.S.; Zhang, Q.H.; Huang, X.; Fu, X.Q.; Qi, S.T.; Wang, Y.P.; Hou, Y.; Sheng, J.; Sun, Q.Y. Icaritin causes sustained ERK1/2 activation and induces apoptosis in human endometrial cancer cells. PLoS ONE 2011, 6, e16781.
11. Guo, Y.; Zhang, X.; Meng, J.; Wang, Z.Y. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur. J. Pharmacol. 2011, 658, 114–122.
12. Li, S.; Priceman, S.J.; Xin, H.; Zhang, W.; Deng, J.; Liu, Y.; Huang, J.; Zhu, W.; Chen, M.; Hu, W.; et al. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS ONE 2013, 8, e81657.
13. Zheng, Q.; Liu, W.W.; Li, B.; Chen, H.J.; Zhu, W.S.; Yang, G.X.; Chen, M.J.; He, G.Y. Anticancer effect of icaritin on human lung cancer cells through inducing S phase cell cycle arrest and apoptosis. J. Huazhong Univ. Sci. Technol. Med. Sci. 2014, 34, 497–503.
14. Zhu, S.; Wang, Z.; Li, Z.; Peng, H.; Luo, Y.; Deng, M.; Li, R.; Dai, C.; Xu, Y.; Liu, S.; et al. Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. Oncotarget 2015, 6, 10460–10472.
15. Li, Q.; Huai, L.; Zhang, C.; Wang, C.; Jia, Y.; Chen, Y.; Yu, P.; Wang, H.; Rao, Q.; Wang, M.; et al. Icaritin induces AML cell apoptosis via the MAPK/ERK and PI3K/AKT signal pathways. Int. J. Hematol. 2013, 97, 617–623.
16. Zhu, J.; Li, Z.; Zhang, G.; Meng, K.; Kuang, W.; Li, J.; Zhou, X.; Li, R.; Peng, H.; Dai, C.; et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3/AKT signalings. PLoS ONE 2011, 6, e23720.
17. Xu, B.; Jiang, C.; Han, H.; Liu, H.; Tang, M.; Liu, L.; Ji, W.; Lu, X.; Yang, X.; Zhang, Y.; et al. Icaritin inhibits the invasion and epithelial-to-mesenchymal transition of glioblastoma cells by targeting EMMPRIN via PTEN/AKt/HIF-1alpha signalling. Clin. Exp. Pharmacol. Physiol. 2015, 42, 1296–1307.
18. Mali, S.B. Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer. Oral Oncol. 2015, 51, 565–569.
19. Lai, S.Y.; Johnson, F.M. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches. Drug Resist. Updates 2010, 13, 67–78.
20. Fan, T.F.; Bu, L.L.; Wang, W.M.; Ma, S.R.; Liu, J.F.; Deng, W.W.; Mao, L.; Yu, G.T.; Huang, C.F.; Liu, B.; et al. Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC. Oncotarget 2015, 6, 43581–43593.
21. Yu, H.; Lee, H.; Herrmann, A.; Buettner, R.; Jove, R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer 2014, 14, 736–746.
22. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. Nat. Rev. Cancer 2009, 9, 798–809.
23. Shen, S.; Niso-Santano, M.; Adjemian, S.; Takehara, T.; Malik, S.A.; Minoux, H.; Souquere, S.; Marino, G.; Lachkar, S.; Senovilla, L.; et al. Cytoplasmic STAT3 represses autophagy by inhibiting PKR activity. Mol. Cell 2012, 48, 667–680.
24. Sen, M.; Pollock, N.I.; Black, J.; DeGrave, K.A.; Wheeler, S.; Freilino, M.L.; Joyce, S.; Lui, V.W.; Zeng, Y.; Chiosea, S.I.; et al. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia 2015, 17, 256–264.
25. Peyser, N.D.; Freilino, M.; Wang, L.; Zeng, Y.; Li, H.; Johnson, D.E.; Grandis, J.R. Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer. Oncogene 2016, 35, 1163–1169.
26. Bonner, J.A.; Yang, E.S.; Trummell, H.Q.; Nowsheen, S.; Willey, C.D.; Raisch, K.P. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiother. Oncol. 2011, 99, 339–343.
27. Sen, M.; Thomas, S.M.; Kim, S.; Yeh, J.I.; Ferris, R.L.; Johnson, J.T.; Duvvuri, U.; Lee, J.; Sahu, N.; Joyce, S.; et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: Implications for cancer therapy. Cancer Discov. 2012, 2, 694–705.
28. Bendris, N.; Lemmers, B.; Blanchard, J.M. Cell cycle, cytoskeleton dynamics and beyond: The many functions of cyclins and CDK inhibitors. Cell Cycle 2015, 14, 1786–1798.
29. Galluzzi, L.; Lopez-Soto, A.; Kumar, S.; Kroemer, G. Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity 2016, 44, 221–231.
30. Agarwal, A.; Mahfouz, R.Z.; Sharma, R.K.; Sarkar, O.; Mangrola, D.; Mathur, P.P. Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes. Reprod. Biol. Endocrinol. 2009, 7, 143.
31. Cui, X.; Liu, J.; Bai, L.; Tian, J.; Zhu, J. Interleukin-6 induces malignant transformation of rat mesenchymal stem cells in association with enhanced signaling of signal transducer and activator of transcription 3. Cancer Sci. 2014, 105, 64–71.
32. Brown, M.E.; Bear, M.D.; Rosol, T.J.; Premanandan, C.; Kisseberth, W.C.; London, C.A. Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet. Res. 2015, 11, 206.
33. Leeman-Neill, R.J.; Seethala, R.R.; Singh, S.V.; Freilino, M.L.; Bednash, J.S.; Thomas, S.M.; Panahandeh, M.C.; Gooding, W.E.; Joyce, S.C.; Lingen, M.W.; et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer Prev. Res. 2011, 4, 230–237.
34. Rahman, M.A.; Amin, A.R.; Shin, D.M. Chemopreventive potential of natural compounds in head and neck cancer. Nutr. Cancer 2010, 62, 973–987.
35. Bollrath, J.; Phesse, T.J.; von Burstin, V.A.; Putoczki, T.; Bennecke, M.; Bateman, T.; Nebelsiek, T.; Lundgren-May, T.; Canli, O.; Schwitalla, S.; et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15, 91–102.
36. Shi, L.; Wang, S.; Zangari, M.; Xu, H.; Cao, T.M.; Xu, C.; Wu, Y.; Xiao, F.; Liu, Y.; Yang, Y.; et al. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 2010, 1, 22–33.
37. Jin, L.; Miao, J.; Liu, Y.; Li, X.; Jie, Y.; Niu, Q.; Han, X. Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells. Biomed. Pharmacother. 2016, 85, 287–295.
38. Marino, G.; Niso-Santano, M.; Baehrecke, E.H.; Kroemer, G. Self-consumption: The interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2014, 15, 81–94.
39. Kumar, D.; Shankar, S.; Srivastava, R.K. Rottlerin-induced autophagy leads to the apoptosis in breast cancer stem cells: Molecular mechanisms. Mol. Cancer 2013, 12, 171.
40. Feng, Y.; Ke, C.; Tang, Q.; Dong, H.; Zheng, X.; Lin, W.; Ke, J.; Huang, J.; Yeung, S.C.; Zhang, H. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014, 5, e1088.
41. Eisenberg-Lerner, A.; Bialik, S.; Simon, H.U.; Kimchi, A. Life and death partners: Apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009, 16, 966–975.
42. Song, P.; Ye, L.; Fan, J.; Li, Y.; Zeng, X.; Wang, Z.; Wang, S.; Zhang, G.; Yang, P.; Cao, Z.; et al. Asparaginase induces apoptosis and cytoprotective autophagy in chronic myeloid leukemia cells. Oncotarget 2015, 6, 3861–3873.
43. Warnakulasuriya, S.; Ariyawardana, A. Malignant transformation of oral leukoplakia: A systematic review of observational studies. J. Oral Pathol. Med. 2016, 45, 155–166.
44. Vitale-Cross, L.; Molinolo, A.A.; Martin, D.; Younis, R.H.; Maruyama, T.; Patel, V.; Chen, W.; Schneider, A.; Gutkind, J.S. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prev. Res. 2012, 5, 562–573.